From single excipients to dual excipient platforms in dry powder inhaler products

Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2016-12, Vol.514 (2), p.374-383
Main Authors: Shur, Jagdeep, Price, Robert, Lewis, David, Young, Paul M., Woollam, Grahame, Singh, Dilraj, Edge, Stephen
Format: Article
Language:English
Subjects:
Administration, Inhalation
Drug Compounding - methods
Dry powder inhaler
Dry Powder Inhalers - methods
Excipients
Excipients - chemistry
Formulation
Humans
Inhalation
Lactose - chemistry
Particle Size
Respiratory Therapy - methods
Stearic Acids - chemistry
Surface Properties
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual excipient platform’ has recently been achieved. This article provides an overview of the background and current status of the development of such ‘dual excipient platform’ based DPI products.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2016.05.057